MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)

• Status: Terminated
• Trial end date: 2003-11-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to evaluate the cardiac and metabolic effects of MK0767 in patients with Type 2 Diabetes.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• You are taking at least one medication for high blood sugar

• Age 21 to 80

Exclusion Criteria:

• History of Type 1 Diabetes Mellitus

• Currently on estrogen replacement therapy regimen

• Currently on a weight loss program with ongoing weight loss or taking medications for weight loss

• Having surgery 30 days before starting the study

• Have taken any other investigational drug in the past 90 days

• Have Hepatitis B or C

• Active liver or gallbladder disease